18:40 , Aug 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Insomnia Mouse studies suggest inhibiting ARNTL could help treat tuberous sclerosis complex (TSC)-associated sleep disorder. In cortical tissue samples from a mouse model of TSC, levels of ARNTL were higher and varied less with circadian...
18:08 , Jul 10, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A 10-gene signature in tumors could help predict survival in breast cancer. In 4,994 breast cancer patients, low tumors levels of a signature based on the expression of 10 genes -- including aryl...
19:38 , Dec 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Head and neck cancer Patient sample, cell culture and mouse studies suggest promoting ARNTL expression could help treat tongue squamous cell carcinoma. In patient tumor samples or three human tongue squamous cell carcinoma cell lines,...
07:00 , Apr 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Aryl hydrocarbon receptor nuclear translocator-like 2 (ARNTL2; BMAL2)

Cancer INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting ARNTL2 could help treat metastatic lung adenocarcinoma. In patient samples, ARNTL2 levels were higher in metastatic tumors and primary tumors that metastasized than in...
07:00 , Jun 18, 2015 |  BC Innovations  |  Product R&D

Pocketing cancer

Although the hypoxic response pathway has long been of interest in cancer, directly blocking hypoxia-inducible factors (HIFs) has been a problem because of the lack of an obvious or easily accessible binding site. Using a...
07:00 , Jun 4, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-155 (miR-155); aryl hydrocarbon receptor nuclear translocator-like (ARNTL; BMAL1)

Inflammation INDICATION: Inflammation In vitro and mouse studies suggest inhibiting miR-155 could help reduce inflammation in sepsis. In mouse models of sepsis, zeitgeber time 12 (ZT12) - the transition to the active phase of the day -...
07:00 , Oct 27, 2011 |  BC Innovations  |  Cover Story

Much ado about TDO

While companies are pursuing indolamine 2,3-dioxygenase inhibitors for cancer, German academics have identified an alternate tryptophan metabolism pathway mediated by an enzyme called tryptophan 2,3-dioxygenase that tumors exploit to grow and evade the immune system.1...
07:00 , May 21, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease ...